A study showing the safety and effectiveness of a leadless cardiac pacemaker for right ventricular pacing has set the stage for research into a novel dual-chamber device that would serve a significantly broader population of patients with abnormal heart rhythms. A global clinical trial of the first-in-human dual chamber system is now enrolling, with Mount Sinai as a key investigative site.
